Category: piperazines

On November 30, 2013, Kavitha, Channappa N.; Jasinski, Jerry P.; Anderson, Brian J.; Yathirajan, H. S.; Kaur, Manpreet published an article.Safety of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone The title of the article was 1-[4-(4-Hydroxyphenyl)piperazin-1-yl]ethanone. And the article contained the following:

In the title compound, C12H16N2O2, the piperazine ring has a chair conformation. The dihedral angle between the mean planes of the benzene ring and the acetyl group is 48.7 (1)°. In the crystal, mols. are linked via O-H···O hydrogen bonds, forming chains propagating along [010]. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Safety of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

The Article related to hydroxyphenylpiperazinylethanone crystal structure, Crystallography and Liquid Crystals: Polytypism, Polymorphism, Crystal Phase Transitions, Ordering, Amorphization and other aspects.Safety of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 31, 2022, Szeto, Andy H.; Bucci, Tyler; Deal, Allison; Zhu, Anqi; Ahmad, Majd; Cass, Amanda S.; Sketch, Margaret R.; Kemper, Ryan; Zeidner, Joshua F.; Foster, Matthew C.; Muluneh, Benyam; Crona, Daniel J. published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia. And the article contained the following:

Tyrosine kinase inhibitors (TKIs) are the front-line therapy for chronic myeloid leukemia (CML), where phase 3 clin. trials have demonstrated their safety and efficacy. However, trial patients may not be representative of real-world patients (RWPs). To evaluate RWP clin. factors associated with effectiveness and safety in CML patients treated with TKIs. Patients with CML treated with at least 30 days of imatinib, dasatinib, nilotinib, or bosutinib between 2014 and 2018 were included. Patients were stratified into categories based on the number of factors that would have precluded enrollment into pivotal TKI phase 3 trials (0, 1, ≥2). End points included complete hematol. response (CHR), early mol. response (EMR), major mol. response (MMR), adverse event (AE)-induced dose decreases, treatment interruptions, and treatment discontinuations. Final analyses included 174 patients. Patients with ≥2 factors had a higher risk of dose decreases (relative risk = 1.54; 95% CI = 1.02-2.34; P = 0.02) and a shorter time to dose decrease (hazard ratio = 2.43; 95% CI = 1.23-4.97; P = 0.006) compared with patients with 0 factors. Significant differences were observed in CHR at 1 mo and MMR at 3 mo between patients with 0 and ≥2 factors (P = 0.03 and P = 0.04, resp.). Approx. 60% of our RWPs would have been excluded from the pivotal phase 3 TKI trials. These data suggest that RWPs require more precise dosing to achieve CML clin. milestones and to mitigate AEs, but findings should be validated prospectively. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to imatinib dasatinib anticancer agent chronic myeloid leukemia adult, adverse drug events, bosutinib, chronic myeloid leukemia, dasatinib, effectiveness, imatinib, nilotinib, real-world patients, tyrosine kinase inhibitors and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 6, 2003, Stankovic, Slobodan; Mitov, Slobodan; Stanojevic, Caslav published a patent.Synthetic Route of 86393-32-0 The title of the patent was A process for synthesis of antibiotic fluoroquinolonic acid derivatives. And the patent contained the following:

A simple and convenient procedure for obtaining antibiotics of fluoroquinolonic derivatives of general formula (I; where R, R2 = H, C1-4 alkyl; R1 = C1-4 alkyl, cycloalkyl such as cyclopropyl), and/or salts and hydrates thereof, in particular ciprofloxacin and norfloxacin, and is developed by amination of piperazine or piperazine derivatives (II; R = same as above) with the 6-fluoro-7-chloro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid derivative of general formula (III; R1 , R2 = same as above) in an inert solvent of pharmacopoeic purity, at risen temperature The process is characterized in lower reaction temperature, atm. pressure reaction, tech. simplicity of the procedure of purification by conversion and isolation in the form of pharmaceutically acceptable salts, increased yields, reducing cost on the procedure for industrial use, as well as pharmacopoeic purity of the product, enabled their use as the antibiotics in human and veterinary medicine. Thus, a mixture of 49.25 g 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, 72.25 g piperazine, and 250 cm3 of DMSO was heated for 1.5 to 2 h at 140°, cooled to 70°, treated with 985 cm3 distilled water, and then treated with 62.5 cm3 concentrated HCl with stirring and cooling. Formed suspension was filtered and the precipitate was rinsed with distilled water, suspended in water, dissolved by addition of 2 mol/dm3 HCl, treated with active charcoal, heated with stirring at 50°, and filtered. To the filtrate was added 2 mol/dm3 NaOH with stirring and cooling and the formed suspension was filtered. The precipitate was rinsed with distilled water, suspended in water with stirring, treated with 60 cm3 2 mol/dm3 HCl, heated for 30 min at 75-80°, and added to 1,750 cm3 absolute ethanol. The mixture was cooled to 0-5° and filtered, and the precipitate was rinsed three times with 30 cm3 absolute ethanol each time, and dried in vacuum drier at 80° to give 49.46 g ciprofloxacin hydrochloride monohydrate (1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazinoquinoline-3-carboxylic acid hydrochloride monohydrate) as white crystals having m.p. 308-310° (decomposition) in 73% yield. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Synthetic Route of 86393-32-0

The Article related to fluoroquinolonic acid preparation antibiotic, ciprofloxacin hydrochloride monohydrate preparation antibiotic, fluoropiperazinodihydrooxoquinolinecarboxylic acid preparation antibiotic, norfloxacin preparation antibiotic and other aspects.Synthetic Route of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 7, 2022, Huo, Changxin; Wang, Hexiang; Lv, Gang; Wang, Zhiwei; Liu, Huaqing published a patent.COA of Formula: C15H29N3O2 The title of the patent was Degradation of bruton’s tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use. And the patent contained the following:

Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof. The title compounds I [ring A and B = (independently) an aromatic ring comprising 0-3 heteroatoms selected from N, S and O as ring member(s); Z1-Z4 = (independently) N or CRz; L = (independently) a bond, alkylene, O, etc.; m, n and q = (independently) 0-4; t = 0-2; R1 and R2 = (independently) H, alkyl, cycloalkyl, etc.; R3, R5 and R6 = (independently) H, halo, alkyl, etc.; Rz = the bond between moiety and Linker-Degron moiety, H, halo, etc.; the Linker = a bond or a divalent linking group; and the Degron = E3 Ubiquitin ligase moiety] or pharmaceutically acceptable salts thereof, were prepared E.g., a multi-step synthesis of II, starting from 4-phenoxybenzaldehyde and 4-methylbenzenesulfonohydrazide, was described. Exemplified compounds I were evaluated for their activity as BTK degradation (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).COA of Formula: C15H29N3O2

The Article related to bifunctional compound preparation bruton’s tyrosine kinase btk degradation, targeted protein degrader btk e3 ubiquitin ligase bifunctional compound, btk inhibitor e3 ligase conjugation bifunctional compound preparation and other aspects.COA of Formula: C15H29N3O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 1, 2018, Fan, Jianjia; Zhao, Rui Qi; Parro, Cameron; Zhao, Wenchen; Chou, Hsien-Ya; Robert, Jerome; Deeb, Tarek Z.; Raynoschek, Carina; Barichievy, Samantha; Engkvist, Ola; Maresca, Marcello; Hicks, Ryan; Meuller, Johan; Moss, Stephen J.; Brandon, Nicholas J.; Wood, Michael W.; Kulic, Iva; Wellington, Cheryl L. published an article.Recommanded Product: N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide The title of the article was Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway. And the article contained the following:

ApoE is the primary lipid carrier within the CNS and the strongest genetic risk factor for late onset Alzheimer’s disease (AD). apoE is primarily lipidated via ABCA1, and both are under transcriptional regulation by the nuclear liver X receptor (LXR). Considerable evidence from genetic (using ABCA1 overexpression) and pharmacol. (using synthetic LXR agonists) studies in AD mouse models suggests that increased levels of lipidated apoE can improve cognitive performance and, in some strains, can reduce amyloid burden. However, direct synthetic LXR ligands have hepatotoxic side effects that limit their clin. use. Here, we describe a set of small mols., previously annotated as antagonists of the purinergic receptor, P2X7, which enhance ABCA1 expression and activity as well as apoE secretion, and are not direct LXR ligands. Furthermore, P2X7 is not required for these mols. to induce ABCA1 upregulation and apoE secretion, demonstrating that the ABCA1 and apoE effects are mechanistically independent of P2X7 inhibition. Hence, we have identified novel dual activity compounds that upregulate ABCA1 across multiple CNS cell types, including human astrocytes, pericytes, and microglia, through an indirect LXR mechanism and that also independently inhibit P2X7 receptor activity. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).Recommanded Product: N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide

The Article related to astrocytoma hepatoma cell abca1 apoe lxr, alzheimer’s disease, p2x7 receptor, adenosine 5′-triphosphate-binding cassette transporter a1, apolipoprotein e, astrocyte, brain, nuclear receptors/liver x receptor and other aspects.Recommanded Product: N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Deb, Suryyani; Boknaes, Niklas; Sjoestroem, Clara; Tharmakulanathan, Anjana; Lotfi, Kourosh; Ramstroem, Sofia published an article in 2020, the title of the article was Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?.Category: piperazines And the article contains the following content:

Since their introduction, tyrosine kinase inhibitors (TKIs, eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib) have revolutionized the treatment of chronic myeloid leukemia (CML). However, long-term treatment with TKIs is associated with serious adverse events including both bleeding and thromboembolism. Exptl. studies have shown that TKIs can cause platelet dysfunction. Herein, we present the first side-by-side investigation comparing the effects of currently used TKIs on platelet function and thrombin generation when used in clin. relevant concentrations A flow cytometry multiparameter protocol was used to study a range of significant platelet activation events (fibrinogen receptor activation, alpha granule, and lysosomal exocytosis, procoagulant membrane exposure, and mitochondrial permeability changes). In addition, thrombin generation was measured in the presence of TKIs to assess the effects on global hemostasis. Results show that dasatinib generally inhibited platelet function, while bosutinib, nilotinib, and ponatinib showed less consistent effects. In addition to these general trends for each TKI, we observed a large degree of interindividual variability in the effects of the different TKIs. Interindividual variation was also observed when blood from CML patients was studied ex vivo with whole blood platelet aggregometry, free oscillation rheometry (FOR), and flow cytometry. Based on the donor responses in the side-by-side TKI study, a TKI sensitivity map was developed. We propose that such a sensitivity map could potentially become a valuable tool to help in decision-making regarding the choice of suitable TKIs for a CML patient with a history of bleeding or atherothrombotic disease. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines

The Article related to bosutinib nilotinib anticancer tyrosine kinase inhibitor platelet myeloid leukemia, chronic myeloid/myelogenous leukemia, coagulation, hemostasis, personalized medicine, platelets, tyrosine kinase inhibitors and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 15, 2020, Ramesh, Deepthi; Joji, Annu; Vijayakumar, Balaji Gowrivel; Sethumadhavan, Aiswarya; Mani, Maheswaran; Kannan, Tharanikkarasu published an article.SDS of cas: 67914-60-7 The title of the article was Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis. And the article contained the following:

Indole chalcones were designed and synthesized as a promising set of compounds against H37Rv strain of Mycobacterium tuberculosis. Within this library of compounds, (E)-1-(furan-3-yl)-3-(1H-indol-3-yl)prop-2-en-1-one (18), (E)-3-(1H-indol-3-yl)-1-(thiophen-2-yl)prop-2-en-1-one (20) and (E)-2-((1H-indol-2-yl)methylene)cyclopentan-1-one (24) displayed high anti-tubercular activity at 50 μg/mL with MIC values of 210, 197 and 236 μM resp. The in-silico studies revealed that compound 18 exhibit binding modes similar to FAS-II inhibitors like INH or Thiolactomycin against KasA protein. Cytotoxicity assay results suggest that the compounds 18, 20 and 24 are non-cytotoxic to human megakaryocytes and murine B cells. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).SDS of cas: 67914-60-7

The Article related to indole chalcones tuberculostatics mycobacterium, anti-tubercular, cytotoxicity, h(37)rv strain, indole chalcones, kasa protein, luciferase reporter mycobacteriophages (lrp), mycobacterium tuberculosis, sars and other aspects.SDS of cas: 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On October 31, 2005, He, Qiuqin; Liu, Chaomei; Men, Xiufeng; Zhao, Jingxia published an article.Electric Literature of 67914-60-7 The title of the article was Synthesis and antifungal activity of 1-(1H-1,2,4-triazol-1-yl)-2-(3,3-dimethyl)-3-[(4-substituted)-1-piperazinyl]-2-propanol derivatives. And the article contained the following:

Antifungal activity of triazole derivatives bearing a side chain containing tert-Bu and 4-[4-(alkoxy)phenyl]-1-piperazine was studied and their antifungal activities were compared with that of fluconazole and itraconazole. According to the structure of fluconazole, ten target compounds were designed and synthesized. The target compounds thus prepared included α-(1,1-dimethylethyl)-4-[4-(pyridinylmethoxy)phenyl]-α-[(1H-1,2,4-triazolyl)methyl]-1-piperazineethanol isomers, α-(1,1-dimethylethyl)-4-[4-[(2-methylphenyl)methoxy]phenyl]-α-[(1H-1,2,4-triazolyl)methyl]-1-piperazineethanol, α-(1,1-dimethylethyl)-4-(4-ethoxyphenyl)-α-[(1H-1,2,4-triazolyl)methyl]-1-piperazineethanol, etc. The MIC80 of all the target compounds were determined by the method recommended by the national committee for clin. laboratory standards (NCCLS) using the RPMI-1640 test medium. All the target compounds were firstly reported. The results of the preliminary antifungal test showed that all the target compounds had potent antifungal activities to a certain extent. The activities of four target compounds were 4 times as high as that of fluconazole and equal to that of itraconazole against Candida albicans in vitro. More hydrophobic groups can be introduced to design triazole compounds and stereochem. have important influence on the antifungal activities of the target compounds The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Electric Literature of 67914-60-7

The Article related to butyl triazole antifungal activity, piperazineethanol pyridinylmethoxy phenyl triazolylmethyl preparation antifungal agent, triazolylmethyl alkoxyphenylmethyl piperazineethanol preparation antifungal agent and other aspects.Electric Literature of 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2022, Yokoyama, Yuta; Nozawa, Eiji; Morita, Miho; Ishikawa, Emi; Mori, Takehiko; Sakurai, Masatoshi; Kikuchi, Taku; Matsuki, Eri; Yamazaki, Rie; Kataoka, Keisuke; Jibiki, Aya; Kawazoe, Hitoshi; Suzuki, Sayo; Nakamura, Tomonori published an article.Category: piperazines The title of the article was Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection. And the article contained the following:

Dasatinib, nilotinib, and bosutinib, second-generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third-generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatog.-tandem mass spectrometry assays for simultaneous quantification of the four TKIs in human serum have been reported in the literature, a high-performance liquid chromatog. (HPLC) assay that simultaneously quantifies these compounds has not yet been developed. This study aims to establish and validate an efficient HPLC anal. method using a photodiode array (PDA) detector for the simultaneous quantification of the four TKIs. Calibration standards were prepared by serial dilution of serum samples containing the four TKIs, followed by solid-phase extraction The four TKIs were eluted in order within 10 min using a binary HPLC gradient system. The calibration ranges were 2-500 ng/mL for dasatinib, 100-5000 ng/mL for nilotinib, and 10-500 ng/mL for bosutinib and ponatinib. Intra-day and inter-day precision and accuracy values were found to be in accordance with the U. S. Food and Drug Administration guidelines. The recovery rates were 92.9%-96.0%, 80.7%-86.1%, 91.6%-99.0%, and 86.4%-92.6% for dasatinib, nilotinib, bosutinib, and ponatinib, resp. To the best of our knowledge, this is the first report of an HPLC-PDA anal. method that allows efficient simultaneous quantification of the four TKIs in the serum of patients with CML. We believe that the method developed herein can improve the efficiency of therapeutic drug monitoring in patients with CML in clin. practice. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines

The Article related to photodiode dasatinib nilotinib bosutinib ponatinib high performance liquid chromatog, chronic myeloid leukemia, high-performance liquid chromatography, photodiode array detector, tyrosine kinase inhibitor and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 31, 2020, Nadaf, Afra Quasar A.; Najare, Mahesh S.; Garbhagudi, Manjunatha; Mantur, Shivaraj; Sunagar, Manjunath G.; Gaonkar, Supreet; Joshi, Shrinivas; Khazi, Imtiyaz Ahmed M. published an article.Recommanded Product: 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone The title of the article was Synthesis of 6-[4-(4-Propoxyphenyl)piperazin-1-yl]-9H-purine Derivatives as Antimycobacterial and Antifungal Agents: In Vitro Evaluation and In Silico Study. And the article contained the following:

A series of novel alkyl substituted purines were synthesized. 6-[4-(4-Propoxyphenyl)piperazin-1-yl]-9H-purine was used as the key starting material, which was synthesized via a multistep protocol and finally subjected for N-alkylation with various alkyl halides with an aim to get prospective antimicrobial agents. The structures of the novel compounds were established by substantiating them through spectral techniques like 1H-NMR, 13C-NMR, FT-IR and EI-MS. They were explored for antitubercular activity against Mycobacterium tuberculosis H37RV. Furthermore, they were checked for their antimicrobial activity concerning bacterial and fungal strains. The title compounds exhibited considerable antimicrobial activity without any significant toxicity. In silico studies depicted their good binding profile against Mycobacterium tuberculosis enoyl reductase (InhA; PDB ID: 4TZK) and Candida albicans dihydrofolate reductase (PDB ID: 1AI9). The title compounds obeyed Lipinski’s parameters and have exhibited good drug-like properties. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Recommanded Product: 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

The Article related to propoxyphenyl piperazinyl purine preparation antimicrobial antibacterial antifungal, mycobacterium tuberculosis, docking study, antimicrobial activity, antitubercular activity, propoxyphenylpiperazin-1-yl and other aspects.Recommanded Product: 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics